Skip to content
Wenlo
Sign in
← Markets

Regeneron Pharmaceuticals, Inc.

Andrew J Murphy (Co-Chief Scientific Officer) sells REGN shares

4REGNFiled Nov 18, 2026, 4:07 PM ET· Period Nov 16, 2026

AI-generated summary

Co-Chief Scientific Officer Andrew J Murphy exercised 17,000 options at an average price of $381.92, had 11,989 shares withheld for taxes at an average price of $960.02, and sold 5,011 shares at an average price of $957.76. After these transactions, the insider directly held 46,779 shares. The transactions were executed under a Rule 10b5-1 trading plan adopted on May 7, 2026.

Key facts

Insider
Andrew J Murphy · Co-Chief Scientific Officer

Rule 10b5-1 plan · adopted May 7, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Nov 16, 2026M · exercise or conversion of a derivativeFootnotes F1+17,000$381.92$6,492,640.0063,779Direct
Nov 16, 2026F · tax withholdingFootnotes F1−11,989$960.02$11,509,679.7851,790Direct
Nov 17, 2026S · open-market saleFootnotes F1−93$949.69$88,321.1751,697Direct
Nov 17, 2026S · open-market saleFootnotes F1, F2−74$950.61$70,345.1451,623Direct
Nov 17, 2026S · open-market saleFootnotes F1, F3−298$951.75$283,621.5051,325Direct
Nov 17, 2026S · open-market saleFootnotes F1, F4−220$952.75$209,605.0051,105Direct
Nov 17, 2026S · open-market saleFootnotes F1, F5−671$953.69$639,925.9950,434Direct
Nov 17, 2026S · open-market saleFootnotes F1, F6−313$954.45$298,742.8550,121Direct
Nov 17, 2026S · open-market saleFootnotes F1, F7−313$955.48$299,065.2449,808Direct
Nov 17, 2026S · open-market saleFootnotes F1, F8−346$956.70$331,018.2049,462Direct
Nov 17, 2026S · open-market saleFootnotes F1, F9−202$957.53$193,421.0649,260Direct
Nov 17, 2026S · open-market saleFootnotes F1, F10−244$958.27$233,817.8849,016Direct
Nov 17, 2026S · open-market saleFootnotes F1, F11−506$959.45$485,481.7048,510Direct
Nov 17, 2026S · open-market saleFootnotes F1, F12−257$960.65$246,887.0548,253Direct
Nov 17, 2026S · open-market saleFootnotes F1, F13−584$961.45$561,486.8047,669Direct
Nov 17, 2026S · open-market saleFootnotes F1, F14−295$962.70$283,996.5047,374Direct
Nov 17, 2026S · open-market saleFootnotes F1, F15−255$963.60$245,718.0047,119Direct
Nov 17, 2026S · open-market saleFootnotes F1, F16−340$964.36$327,882.4046,779Direct
Nov 16, 2026M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F1, F17−17,000$0.00$0.000Direct
Footnotes
  1. F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026.
  2. F2 Represents volume-weighted average price of sales of 74 shares of Company stock on November 17, 2026 at prices ranging from $950.50 to $950.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  3. F3 Represents volume-weighted average price of sales of 298 shares of Company stock on November 17, 2026 at prices ranging from $951.41 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  4. F4 Represents volume-weighted average price of sales of 220 shares of Company stock on November 17, 2026 at prices ranging from $952.54 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  5. F5 Represents volume-weighted average price of sales of 671 shares of Company stock on November 17, 2026 at prices ranging from $953.18 to $953.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  6. F6 Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $954.26 to $954.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  7. F7 Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $955.02 to $955.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  8. F8 Represents volume-weighted average price of sales of 346 shares of Company stock on November 17, 2026 at prices ranging from $956.17 to $956.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price
  9. F9 Represents volume-weighted average price of sales of 202 shares of Company stock on November 17, 2026 at prices ranging from $957.00 to $957.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  10. F10 Represents volume-weighted average price of sales of 244 shares of Company stock on November 17, 2026 at prices ranging from $958.12 to $958.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  11. F11 Represents volume-weighted average price of sales of 506 shares of Company stock on November 17, 2026 at prices ranging from $959.03 to $959.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  12. F12 Represents volume-weighted average price of sales of 257 shares of Company stock on November 17, 2026 at prices ranging from $960.10 to $960.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  13. F13 Represents volume-weighted average price of sales of 584 shares of Company stock on November 17, 2026 at prices ranging from $961.07 to $961.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  14. F14 Represents volume-weighted average price of sales of 295 shares of Company stock on November 17, 2026 at prices ranging from $962.17 to $962.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  15. F15 Represents volume-weighted average price of sales of 255 shares of Company stock on November 17, 2026 at prices ranging from $963.28 to $963.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  16. F16 Represents volume-weighted average price of sales of 340 shares of Company stock on November 17, 2026 at prices ranging from $964.03 to $964.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  17. F17 The stock option award vested in four equal annual installments, commencing one year after the date of grant.

More REGN filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.